Qube Research & Technologies (QRT)
ANIK icon

Qube Research & Technologies (QRT)’s Anika Therapeutics ANIK Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,523
Closed -$159K – 3515
2025
Q4 		$159K Sell
16,523
-905
-5% -$8.67K ﹤0.01% 3100
2025
Q3 		$164K Sell
17,428
-4,230
-20% -$40.4K ﹤0.01% 2980
2025
Q2 		$229K Sell
21,658
-20,906
-49% -$264K ﹤0.01% 2882
2025
Q1 		$640K Sell
42,564
-6,173
-13% -$103K ﹤0.01% 2458
2024
Q4 		$802K Buy
48,737
+22,812
+88% +$450K ﹤0.01% 2290
2024
Q3 		$640K Buy
25,925
+17,939
+225% +$465K ﹤0.01% 2191
2024
Q2 		$202K Sell
7,986
-10,465
-57% -$271K ﹤0.01% 2422
2024
Q1 		$469K Buy
18,451
+1,738
+10% +$42.1K ﹤0.01% 2573
2023
Q4 		$379K Sell
16,713
-13,240
-44% -$274K ﹤0.01% 2454
2023
Q3 		$558K Buy
+29,953
New +$621K ﹤0.01% 1978

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Qube Research & Technologies (QRT)'s ANIK Position: Q1 2026 in Review

Qube Research & Technologies (QRT) sold out of Anika Therapeutics (ANIK) in Q1 2026, closing a stake of 16,523 shares — an estimated $159K sold.

Qube Research & Technologies (QRT) first reported a position in ANIK in Q3 2023 and held it in 10 quarters. The position peaked at $802K in Q4 2024. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.

  • Qube Research & Technologies (QRT) reported no remaining Anika Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 16,523 Anika Therapeutics shares in Q1 2026, an estimated $159K.
  • Qube Research & Technologies (QRT) first reported a position in Anika Therapeutics in Q3 2023 and held it in 10 quarters.
  • Qube Research & Technologies (QRT)'s Anika Therapeutics position peaked at $802K in Q4 2024.
  • 130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.